相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri et al.
DIABETES OBESITY & METABOLISM (2022)
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2022)
Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities
Kris Vijay et al.
CARDIORENAL MEDICINE (2022)
Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling
Patrick Andre et al.
FRONTIERS IN MEDICINE (2022)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE
Ian H. de Boer et al.
KIDNEY INTERNATIONAL (2022)
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx et al.
CIRCULATION (2022)
Liraglutide treatment improves endothelial function in theLdlr-/-mouse model of atherosclerosis and affects genes involved in vascular remodelling and inflammation
Katrine Dahl Bjornholm et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2021)
Bases para la creación de las unidades clínicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN
Rafael de la Espriella et al.
REC: CardioClinics (2021)
Management of Heart Failure Patient with CKD
Debasish Banerjee et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2021)
Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice
Mai Sugahara et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
Marie-Eve Piche et al.
CIRCULATION RESEARCH (2020)
The tubular hypothesis of nephron filtration and diabetic kidney disease
Volker Vallon et al.
NATURE REVIEWS NEPHROLOGY (2020)
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure The Need for Further Evidence Generation and Practice Guidelines Optimization
Muhammad Shahzeb Khan et al.
CIRCULATION (2020)
Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study
Antoni Sicras-Mainar et al.
Revista española de cardiología (English ed.) (2020)
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
Edmund Y. M. Chung et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America
Shannon M. Dunlay et al.
JOURNAL OF CARDIAC FAILURE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Heart Failure in Type 2 Diabetes Mellitus Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies
Helena C. Kenny et al.
CIRCULATION RESEARCH (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Update on Diabetic Nephropathy: Core Curriculum 2018
Kausik Umanath et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Milton Packer et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Apelin Is a Negative Regulator of Angiotensin II-Mediated Adverse Myocardial Remodeling and Dysfunction
Zhen-Zhou Zhang et al.
HYPERTENSION (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Epidemiology in diabetes mellitus and cardiovascular disease
Wenjun Fan
CARDIOVASCULAR ENDOCRINOLOGY (2017)
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Robert J. Smith et al.
DIABETES CARE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Heart Disease and Stroke Statistics-2015 Update A Report From the American Heart Association
Dariush Mozaffarian et al.
CIRCULATION (2015)
Endothelin and endothelin antagonists in chronic kidney disease
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Bianca Hemmingsen et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Cigarette Smoking and the Association with Glomerular Hyperfiltration and Proteinuria in Healthy Middle-Aged Men
Isseki Maeda et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
International day for the evaluation of abdominal obesity (IDEA) -: A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries
Beverley Balkau et al.
CIRCULATION (2007)
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
Hirofumi Makino et al.
DIABETES CARE (2007)
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
分享论文
